Comparing Prenetics Global (NASDAQ:PRE) & GH Research (NASDAQ:GHRS)

Prenetics Global (NASDAQ:PRE) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for Prenetics Global and GH Research, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prenetics Global	1	0	3	0	2.50
GH Research	1	1	9	0	2.73

Prenetics Global presently has a consensus price target of $32.33, indicating a potential upside of 79.53%. GH Research has a consensus price target of $40.13, indicating a potential upside of 139.27%. Given GH Research’s stronger consensus rating and higher possible upside, analysts clearly believe GH Research is more favorable than Prenetics Global.

Risk and Volatility

Prenetics Global has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, GH Research has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.

Insider and Institutional Ownership

25.0% of Prenetics Global shares are owned by institutional investors. Comparatively, 56.9% of GH Research shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Prenetics Global and GH Research”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prenetics Global	$92.39 million	3.28	-$58.32 million	($4.02)	-4.48
GH Research	N/A	N/A	-$48.26 million	($0.80)	-20.96

GH Research has lower revenue, but higher earnings than Prenetics Global. GH Research is trading at a lower price-to-earnings ratio than Prenetics Global, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Prenetics Global and GH Research’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prenetics Global	-61.33%	-19.07%	-15.38%
GH Research	N/A	-16.30%	-15.77%

Summary

GH Research beats Prenetics Global on 9 of the 12 factors compared between the two stocks.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.